April 07, 2017
RealTime Dynamix™: Psoriasis US Q2
The Psoriasis market continues to grow, driven by a growing treatment population and the continued uptake of biologics and advanced therapies. In particular, the IL-17 class shows rapid growth, with both Cosentyx (Novartis) and 2016 launched Taltz from Eli Lilly. Tracking the interplay of these two highly regarded treatments will be central to the 2017 report series as well as assessing the impact of potential new market entrants, including Valeant’s Siliq (brodalumab), Janssen’s guselkumab, Boehringer Ingelheim/AbbVie’s risankizumab, Merck/Sun Pharma’s tildrakizumab, and UCB’s bimekizumab will undoubtedly impact the ever-evolving PsO landscape.
The strategic focus of RealTime Dynamix™ Psoriasis is to provide a robust and independent view of the market changes to patterns of use and the changes in perceptions around new and inline products.
About Spherix Global Insights
Spherix Global Insights is a business intelligence and market research company, specializing in renal, autoimmune, neurologic and rare disease markets. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.